BioArctic's BrainTransporter Opens New Fronts: Oncology Deal and Iqlik Launch Drive Momentum

Q2 2026: Lilly partnership validates platform, Mesenkia marks first oncology foray; Leqembi subcutaneous initiation approved in the U.S.

BIOA-B.ST · Earnings Call · 2026-08-26

Q2 2026: A Transformation Quarter

BioArctic delivered a quarter rich with strategic inflection. The U.S. FDA approval of Iqlik (subcutaneous lecanemab with autoinjector) for initiation treatment — and its U.S. launch this week — positions Leqembi to capture a broader patient pool. As CEO Gunilla Osswald put it, “This means that there is an increased convenience for the patients to have the possibility to get their treatment at home instead of going to the infusion center.” — Gunilla Osswald, CEO · 2026-08-26 The convenience factor is expected to expand access, particularly for patients who live far from infusion clinics or travel frequently.

BrainTransporter's Expanding Universe

The quarter also showcased BioArctic's platform strategy in overdrive. A landmark license and collaboration with Eli Lilly validated the BrainTransporter in neuroscience, while a new research collaboration with Mesenkia — a Swedish biotech — marked the company's first foray into oncology, targeting the aggressive brain cancer glioblastoma. Chief R&D Officer Johanna Fälting highlighted the significance:

Lilly selection of the BrainTransporter for next-generation CNS therapies provide a strong validation from a leading pharmaceutical company and reinforces the importance of efficient blood brain delivery for CNS drug development.
Johanna Fälting, Head of R&D or similar senior R&D role · 2026-08-26

The BrainTransporter collaboration with Lilly, combined with the Mesenkia collaboration, shifts the narrative from a pure Alzheimer's play to a versatile CNS delivery platform with applications across therapeutic areas. As Fälting noted later in the Q&A, the glioblastoma target is "unique" and the combination with the transferrin receptor platform is differentiated.

Leqembi's New Gear: Iqlik Launches

On the commercial front, Leqembi's momentum is tangible. Global Q2 sales reached JPY 29.3 billion (~$184 million), up 27% year-over-year (or ~43% excluding stockpiling effects), with royalties of SEK 179.4 million. Anna-Kaija Gronblad, Chief Commercial Officer, underscored the launch's significance: “So this will increase clearly the momentum as we now move into the second half of 2026.” — Anna-Kaija Gronblad, Senior Executive, possibly Head of Commercial or similar · 2026-08-26 The U.S. began the Iqlik rollout this week; Japan approval is expected imminently with reimbursement later in Q4, while China's approval is targeted for H1 2027. Real-world data presented at AAIC in London reinforced the drug's performance: ~83% of patients had not progressed to more advanced disease after a mean of 17 months. CFO Anders Martin-Lof added that the subcutaneous formulation should drive not only patient uptake but also a higher share of the treatment cost captured by pharma: “Since this is a much more efficient way of delivering these therapeutics, a larger share will end up with the pharmaceutical part of the treatment cost.” — Anders Martin-Lof, CFO or Head of Finance · 2026-08-26 This "game-changer" positioning is a key auto injector advantage over competitors.

Pipeline Progress and Financial Runway

Behind the commercial story, the pipeline continues to advance. The alpha-synuclein program Exidavnemab passed a planned safety review in its Phase IIa EXIST study, supporting progression to Phase IIb, with full study results expected later this year. The follow-on BrainTransporter-enabled antibody BAN2238 is progressing through IND-enabling activities. As Johanna Fälting reminded in the prior quarter, the study design is intentionally cautious: “It's a safety and tolerability study, it's 3 months, and that's a bit too short to see efficacy on biomarkers related to disease modification.” — Johanna Fälting · 2025-11-13 Financially, BioArctic ended Q2 with ~SEK 2 billion in cash (before the $30 million Lilly upfront received in July), enabling continued heavy R&D investment while remaining profitable for the year. This strong position allows the company to pursue multiple shots on goal. As CEO noted in Q1, the company was already seeing broad interest in BrainTransporter: “We have interest both for our drug programs, we have also interest from our BrainTransporter with things that we have done before, and we also have interest in the new stuff that we're working on.” — Gunilla Osswald, CEO · 2026-05-20 Now, that interest has crystallized into concrete partnerships. The Alpha synuclein portfolio remains the closest near-term catalyst, but the platform expansion into oncology and the imminent global Iqlik launches suggest BioArctic is entering a multi-product, multi-therapeutic era.